Nuvectis Pharma, Inc.

NVCT

US67080T1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-03 pm EDT			5-day change	1st Jan Change
8.14 ^USD	+20.41%		+25.23%	-2.40%

Apr. 08	Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	CI
Mar. 14	Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	CI

Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2500 Growth Index

June 23, 2023 at 12:00 am EDT

Latest news about Nuvectis Pharma, Inc.

Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	Apr. 08	CI
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	Mar. 14	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 05	CI
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Nuvectis Pharma Starts Phase 1a Trial of NXP900 in Solid Tumors	23-09-12	MT
Nuvectis Pharma, Inc. Announces Initiation of the NXP900 Phase 1a Clinical Trial	23-09-12	CI
Nuvectis Pharma's NXP800 Cholangiocarcinoma Treatment Candidate Gets US FDA Orphan Drug Label	23-08-17	MT
Nuvectis Gets FDA Orphan Designation for NXP800 in Cholangiocarcinoma	23-08-17	DJ
Nuvectis Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Insider Buy: Nuvectis Pharma	23-07-27	MT
Insider Buy: Nuvectis Pharma	23-07-24	MT
Insider Buy: Nuvectis Pharma	23-07-20	MT
Insider Buy: Nuvectis Pharma	23-07-19	MT
Insider Buy: Nuvectis Pharma	23-07-12	MT
Insider Buy: Nuvectis Pharma	23-07-10	MT
Insider Buy: Nuvectis Pharma	23-06-27	MT
Insider Buy: Nuvectis Pharma	23-06-26	MT
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 3000 Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 3000E Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell Small Cap Completeness Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2500 Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2000 Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2000 Dynamic Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 3000E Growth Index	23-06-23	CI
Nuvectis Pharma, Inc.(NasdaqCM:NVCT) added to Russell 2500 Growth Index	23-06-23	CI

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is an oral small molecule GCN2 activator, which is in a Phase 1b clinical trial for the treatment for platinum resistant, ARID1a-mutated ovarian carcinoma and in an investigator-sponsored clinical trial for the treatment of cholangiocarcinoma. NXP800 activates the GCN2 kinase inducing inhibition of cap-dependent protein translation and activation of the integrated stress response leading to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is undergoing a Phase 1a dose escalation study. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.14 USD

Average target price

22 USD

Spread / Average Target

+170.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NUVECTIS PHARMA, INC.	-2.40%	150M
REGENERON PHARMACEUTICALS, INC.	+8.96%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.43%	104B
ARGENX SE	+4.40%	22.94B
BIONTECH SE	-12.15%	22.34B
GENMAB A/S	-4.36%	19.25B
WUXI APPTEC CO., LTD.	-39.98%	17.08B
BEIGENE, LTD.	-10.04%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+6.79%	14.16B
SAREPTA THERAPEUTICS, INC.	+38.61%	12.63B

Bio Therapeutic Drugs